Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D?

January 17, 2026 updated by: Ali Mohamed Ali ismail, Cairo University
males with diabetes complain impotence in the presence of low vitamin D deficiency. pharacmological treatment of low vitamin D levels is necessary but changing lifestyle by performing exercise is also important

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

forty diabetic men (type 2) who complain presence of low vitamin D and impotence will be divided to group number I and group number II. Both groups will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks. Additionally, Group number I will perform treadmill walking (one hour walking) with moderate intensity. This walking will be performed three times per designed week for twelve weeks.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
    • Giza Governorate
      • Dokki, Giza Governorate, Egypt, 11432
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • diabetic men (forty)
  • type 2 diabetes
  • complaint of erectile dysfucntion (chronic complaint more than 24 months)
  • men with low vitamin D (deiciency in vitamin D)

Exclusion Criteria:

  • cardiac patients
  • respiratory disease patients
  • renal disease
  • liver disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks. Additionally, Group number I will perform treadmill walking (one hour walking) with moderate intensity. This walking will be performed three times per designed week for twelve weeks.
Behavioral: exercise and vitamin D intake
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks. Additionally, Group number I will perform treadmill walking (one hour walking) with moderate intensity. This walking will be performed three times per designed week for twelve weeks.
Active Comparator: group number 2
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks.
Other: vitamin D intake
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
international index of erectile function
Time Frame: it will be measured after 12 weeks
questionnaire used to assess impotence
it will be measured after 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
triglycerides
Time Frame: It will be measured after 12 weeks
it will be assessed in serum
It will be measured after 12 weeks
glycated hemoglubin
Time Frame: It will be measured after 12 weeks
it will be used to assess blood glcuose
It will be measured after 12 weeks
fasting blood glcuose
Time Frame: It will be measured after 12 weeks
it will be used to assess blood glcuose in serum
It will be measured after 12 weeks
body mass index
Time Frame: It will be measured after 12 weeks
it will be measured on empty stomach and bladder
It will be measured after 12 weeks
wasit circumference
Time Frame: it will be measured after 12 weeks
it will be measured at umbilicus level
it will be measured after 12 weeks
high density lipoprotein
Time Frame: It will be measured after 12 weeks
it will be measured in serum
It will be measured after 12 weeks
low density lipoprotein
Time Frame: It will be measured after 12 weeks
it will be measured in serum
It will be measured after 12 weeks
cholesterol
Time Frame: It will be measured after 12 weeks
it will be assessed in serum
It will be measured after 12 weeks
25-hydroxyvitamin D
Time Frame: It will be measured after 12 weeks
it will be assessed in serum as a metabolite of vitamin D
It will be measured after 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 5, 2025

Primary Completion (Estimated)

May 5, 2026

Study Completion (Estimated)

May 5, 2026

Study Registration Dates

First Submitted

January 17, 2026

First Submitted That Met QC Criteria

January 17, 2026

First Posted (Actual)

January 26, 2026

Study Record Updates

Last Update Posted (Actual)

January 26, 2026

Last Update Submitted That Met QC Criteria

January 17, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB000-14233-64

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on exercise and vitamin D intake

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe